You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,394,398


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,394,398
Title:Methods of administering rapamycin analogs with anti-inflammatories using medical devices
Abstract: A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, ##STR00001## This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.
Inventor(s): Toner; John L. (Libertyville, IL), Burke; Sandra E. (Libertyville, IL), Cromack; Keith R. (Gurnee, IL), Mack; Matthew (Chicago, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:11/548,827
Patent Claims:1. An implantable medical device for providing controlled release delivery of drugs comprising: a composition including a therapeutic amount of a first drug and a therapeutic amount of a second drug for treatment or inhibition of neointimal hyperplasia in a blood vessel lumen; wherein said first drug is zotarolimus or a salt thereof; wherein said second drug is dexamethasone or a salt thereof; wherein said therapeutic amount of said second drug improves the effect of said therapeutic amount of said first drug with respect to one effect selected from the group consisting of neointimal area, neointimal thickness, percentage area stenosis, inflammation score, and a combination thereof; and wherein the implantable medical device is a stent or an angioplasty balloon.

2. The implantable medical device according to claim 1, wherein said stent further comprises a coating on at least a portion of the surface of said stent.

3. The implantable medical device according to claim 2, wherein said composition is included in the coating.

4. The implantable medical device according to claim 3, wherein said coating comprises a polymer.

5. The implantable medical device according to claim 4, wherein said polymer comprises a phosphorylcholine polymer.

6. The implantable medical device according to claim 4, wherein said polymer is selected from the group consisting of fluoropolymers, poly(acrylates), silicones, resins, nylons, and poly(amides).

7. The implantable medical device according to claim 3, wherein said therapeutic amount of said first drug is at least 1 .mu.g/mm of stent length on a 3.0.times.15.0 stent.

8. The implantable medical device according to claim 1, wherein said therapeutic amount of said second drug is at least 0.5 .mu.g/mm of stent length on a 3.0.times.15.0 stent.

9. The implantable medical device according to claim 1, further comprising a third therapeutic drug.

10. The implantable medical device according to claim 9, wherein said third therapeutic drug is selected from the group consisting of anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-lipidemic agents, anti-thrombotic agents, thrombolytic agents, their salts and prodrugs, and combinations thereof.

11. The implantable medical device according to claim 9, wherein said third therapeutic drug is a glucocorticosteroid selected from the group consisting of methylprednisolone, prednisolone, prednisone, triamcinolone, dexamethasone, mometasone, beclomethasone, ciclesonide, bedesonide, triamcinolone, clobetasol, flunisolide, loteprednol, budesonide, fluticasone, their salts and prodrugs, and combinations thereof.

12. The implantable medical device according to claim 9, wherein said third therapeutic drug is a steroid hormone selected from the group consisting of estradiol, its salts and prodrugs, and combinations thereof.

13. The implantable medical device according to claim 9, wherein said third therapeutic drug comprises an agent selected from the group consisting of adalimumab, anti-Monocyte Chemoattractant Protein--(MCP-1) antibodies, C-C chemokine receptor type 2 (CCR2) receptor antagonists, anti-Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies, anti-Tumor Necrosis Factor (TNF) antibodies, anti-Interleukin 1 (IL-1) antibodies, anti-Interleukin 2 (IL-2) antibodies, anti-Interleukin 3 (IL-3) antibodies, anti-Interleukin 4 (IL-4) antibodies, anti-Interleukin 8 (IL-8) antibodies, anti-Interleukin 15 (IL-15) antibodies, anti-Interleukin 18 (IL-18) antibodies, their salts and prodrugs, and combinations thereof.

14. The implantable medical device according to claim 9, wherein said third therapeutic drug comprises an anti-proliferative agent selected from the group consisting of alkylating agents, tauromustine, bofumustime, fotemustine, cyclophosphamide, chlorambucil, busulfan, carmustine, lomustine, methotrexate, fluorouracil, 5-bromodeoxyuridine, 6-azacytidine, cytarabine, mercaptopurine, pentostatin, vinca alkaloids vinblastine, vincristine, paclitaxel, nocodazole, indirubin, anthracycline, daunorubicin, daunomycin, plicamycin, antibiotics, doxorubicin, bleomycin, mitomycin, cisplatin, procarbazine, etoposide, teniposide, their salts and prodrugs, and combinations thereof.

15. The implantable medical device according to claim 9, wherein said third therapeutic drug comprises an anti-platelet agent selected from the group consisting of glycoprotein IIB/IIA inhibitors, abciximab, eptifibatide, tirofiban, adenosine reuptake inhibitors, dipyridamole, Adenosine diphosphate (ADP) receptor inhibitors, clopidogrel, ticlopidine, cyclooxygenase inhibitors, acetylsalicylic acid, phosphodiesterase inhibitors, cilostazol, their salts and prodrugs, and combinations thereof.

16. The implantable medical device according to claim 9, wherein said third therapeutic drug comprises an anti-inflammatory agent selected from the group consisting of steroids, dexamethasone, hydrocortisone, fluticasone, clobetasol, mometasone, estradiol, non-steroidal anti-inflammatory agents, acetaminophen, ibuprofen, naproxen, sulindac, piroxicam, mefanamic acid, anti-IL-1 antibodies, anti-IL-2 antibodies, anti-IL-8 antibodies, anti-IL-15 antibodies, anti-IL-18 antibodies, anti-TNF antibodies, their salts and prodrugs, and combinations thereof.

17. The implantable medical device according to claim 8, wherein said third therapeutic drug comprises an anti-thrombotic agent selected from the group consisting of heparins, heparin sulfate, unfractionated heparins, clivarin, dalteparin, enoxaparin, nadroparin, tinzaparin, direct thrombin inhibitors, argatroban, hirudin, hirulog, hirugen, their salts and prodrugs, and combinations thereof.

18. The implantable medical device according to claim 8, wherein said third therapeutic drug comprises an anti-lipidemic agent selected from the group consisting of Hydroxy-Methyl-Glutaryl-Coenzyme A (HMG CoA) reductase inhibitors, mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, fibric acid derivatives, fenofibrate, clofibrate, gemfibrozil, lipid-lowering agents, nicotinic acid, probucol, their salts and prodrugs, and combinations thereof.

19. The implantable medical device according to claim 9, wherein said third therapeutic drug comprises thrombolytic agents selected from the group consisting of streptokinase, urokinase, pro-urokinase, tissue plasminogen activators, alteplase, reteplase, tenectaplase, their salts and prodrugs, and combinations thereof.

20. The implantable medical device according to claim 1, wherein said therapeutic amount of said second drug is at least 1 .mu.g/mm of stent length on a 3.0.times.15.0 stent.

21. The implantable medical device according to claim 1, wherein said first drug reduces formation of neointima by at least 25% versus a non-drug eluting stent in a porcine coronary injury model with 30% overstretch.

22. The implantable medical device according to claim 1, further comprising a ratio of said therapeutic amount of said first drug to said therapeutic amount of said second drug of 1:10 to 10:1.

23. The implantable medical device according to claim 22, wherein said ratio of said therapeutic amount of said first drug to said therapeutic amount of said second drug is about 1:1.

Details for Patent 8,394,398

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 ⤷  Try a Trial 2017-09-26
Genentech, Inc. ACTIVASE alteplase For Injection 103172 11/13/1987 ⤷  Try a Trial 2017-09-26
Genentech, Inc. CATHFLO ACTIVASE alteplase For Injection 103172 09/04/2001 ⤷  Try a Trial 2017-09-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.